# Project Title: Financial Analysis - Fisher Paykel Healthcare | Power BI



Author: [Olivia Nguyen]  
Date: May 2025  
Tools Used: Power BI 

---

## ğŸ“‘ Table of Contents  
I. [ğŸ“Œ Background & Overview](#-background--overview)  
II.[ğŸ“Š Power BI Visualization](#-power-bi-visualization)  
III. [ğŸ” Final Conclusion & Recommendations](#-final-conclusion--recommendations)  
IV. [ğŸ“‚ Dataset Description](#-dataset-description)  


## ğŸ“Œ Background & Overview

### ğŸ“– What is this project about?
This Power BI project analyzes Fisher & Paykel Healthcareâ€™s financial performance in 2024 by examining key Income Statement components. It focuses on revenue, cost structures, profitability, and trends over the past five years. The dashboard delivers clear, data-driven insights to support strategic decision-making and monitor the companyâ€™s financial sustainability.

### ğŸ‘¤ Who is this project for?   
This project is designed for stakeholders in the healthcare and medical device industry, particularly financial analysts, corporate strategists, investors, and business decision-makers with an interest in Fisher & Paykel Healthcare. It supports professionals seeking to understand the company's financial performance, evaluate its operational efficiency, and make informed investment or strategic planning decisions based on key insights from its income statement and balance sheet.

### â“ Business Questions:
- How has Fisher & Paykel Healthcareâ€™s revenue and net income evolved from 2020 to 2024?
- What are the main drivers behind changes in profitability, such as cost of goods sold, R&D expenses, or operational costs?-


## ğŸ“Š Power BI Visualization

### Dashboard 1 Preview
![image](https://github.com/user-attachments/assets/765be3c7-c27c-434d-83ba-c3c57f6c842a)






## ğŸ” Final Conclusion 
 **Key Insights:**

In 2024, the company delivered strong revenue growth, with operating revenue rising 10% to $1,742.8 million, driven by solid performance in both the Hospital and Homecare segments. Gross margin improved to 59.9%, up 95 basis points in constant currency, supported by lower freight costs, manufacturing efficiencies, and strategic pricing initiatives.

Despite this improvement, net income for 2024 declined sharply, primarily due to a 14% increase in operating expensesâ€”reaching $691.0 millionâ€”stemming from continued investment in R&D and the expansion of the global sales force. The decline was further impacted by a land revaluation loss, a tax adjustment, and a product recall. Additionally, net financing expenses rose to $19.6 million as a result of higher interest rates and increased borrowings. The effective tax rate also climbed from 23.7% to 25.3%, and excluding R&D tax credits, it reached 30.5%, contributing to a significant rise in the overall tax burden.

In summary, the 2024 income statement reflects strong operational performance, marked by solid revenue and gross margin growth. While higher expenses and one-off items weighed on reported profit, the company remained profitable and showed resilience through strategic investment and effective cost control.

## ğŸ“‚ Dataset Description

### ğŸŒ Data Source
The data for this project is sourced from the Fisher & Paykel Healthcare Annual Report, which includes detailed financial statements such as the Income Statement and Balance Sheet. The reports are publicly available and can be accessed at: https://www.fphcare.com/nz/corporate/investor/reports/


